Cargando…

Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)

INTRODUCTION: Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US). Better understanding acceptability of treatment with injectable diacetylmorphine among people who use opioids (PWUO) in the US m...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, Sean T., Schneider, Kristin E., Rouhani, Saba, White, Rebecca Hamilton, Morris, Miles, Owczarzak, Jill, Sherman, Susan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120460/
https://www.ncbi.nlm.nih.gov/pubmed/37078710
http://dx.doi.org/10.1080/07853890.2023.2196435
_version_ 1785029184924418048
author Allen, Sean T.
Schneider, Kristin E.
Rouhani, Saba
White, Rebecca Hamilton
Morris, Miles
Owczarzak, Jill
Sherman, Susan G.
author_facet Allen, Sean T.
Schneider, Kristin E.
Rouhani, Saba
White, Rebecca Hamilton
Morris, Miles
Owczarzak, Jill
Sherman, Susan G.
author_sort Allen, Sean T.
collection PubMed
description INTRODUCTION: Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US). Better understanding acceptability of treatment with injectable diacetylmorphine among people who use opioids (PWUO) in the US may expedite future initiatives designed to engage persons in this form of treatment should it become available. The purpose of this research is to examine factors associated with interest in treatment with injectable diacetylmorphine among a sample of PWUO in the US. METHODS: Data are from a cross-sectional study of PWUO in Baltimore City, Maryland. Participants were given a brief description of treatment with injectable diacetylmorphine and then asked to rate their level of interest. We used Poisson regression with robust variance to assess factors associated with interest in treatment with injectable diacetylmorphine. RESULTS: The average age of participants was 48 years, 41% were women, and most (76%) identified as non-Hispanic, Black. The most commonly used substances were non-injection heroin (76%), opioid pain relievers (73%), and non-injection crack/cocaine (73%). Two-thirds of participants (68%) indicated interest in treatment with injectable diacetylmorphine. Factors significantly associated with interest in injectable diacetylmorphine treatment included: having at least a high school education (adjusted prevalence ratio [aPR]: 1.23; 95% confidence interval [CI]: 1.04–1.45), not having health insurance (aPR: 1.23; 95% CI: 1.06–1.44), having ever overdosed (aPR: 1.20; 95% CI: 1.01–1.42), and past utilization of medications for opioid use disorder (aPR: 1.22; 95% CI: 1.01–1.47). Recent non-injection cocaine use was inversely associated with interest in treatment with injectable diacetylmorphine (aPR 0.80; 95% CI: 0.68–0.94). CONCLUSION: The majority of participants reported interest in treatment with injectable diacetylmorphine. Given worsening trends in the addiction and overdose crisis in the US, treatment with injectable diacetylmorphine should be considered as another evidence-based option for treating OUD. KEY MESSAGES: Interest in treatment with injectable diacetylmorphine was high among a sample of people who use opioids in the United States. Factors associated with increased interest in treatment with injectable diacetylmorphine included having at least a high school education, having ever overdosed, and not having health insurance. Past utilization of medications for opioid use disorder was associated with interest in treatment with injectable diacetylmorphine.
format Online
Article
Text
id pubmed-10120460
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-101204602023-04-22 Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA) Allen, Sean T. Schneider, Kristin E. Rouhani, Saba White, Rebecca Hamilton Morris, Miles Owczarzak, Jill Sherman, Susan G. Ann Med Addiction INTRODUCTION: Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US). Better understanding acceptability of treatment with injectable diacetylmorphine among people who use opioids (PWUO) in the US may expedite future initiatives designed to engage persons in this form of treatment should it become available. The purpose of this research is to examine factors associated with interest in treatment with injectable diacetylmorphine among a sample of PWUO in the US. METHODS: Data are from a cross-sectional study of PWUO in Baltimore City, Maryland. Participants were given a brief description of treatment with injectable diacetylmorphine and then asked to rate their level of interest. We used Poisson regression with robust variance to assess factors associated with interest in treatment with injectable diacetylmorphine. RESULTS: The average age of participants was 48 years, 41% were women, and most (76%) identified as non-Hispanic, Black. The most commonly used substances were non-injection heroin (76%), opioid pain relievers (73%), and non-injection crack/cocaine (73%). Two-thirds of participants (68%) indicated interest in treatment with injectable diacetylmorphine. Factors significantly associated with interest in injectable diacetylmorphine treatment included: having at least a high school education (adjusted prevalence ratio [aPR]: 1.23; 95% confidence interval [CI]: 1.04–1.45), not having health insurance (aPR: 1.23; 95% CI: 1.06–1.44), having ever overdosed (aPR: 1.20; 95% CI: 1.01–1.42), and past utilization of medications for opioid use disorder (aPR: 1.22; 95% CI: 1.01–1.47). Recent non-injection cocaine use was inversely associated with interest in treatment with injectable diacetylmorphine (aPR 0.80; 95% CI: 0.68–0.94). CONCLUSION: The majority of participants reported interest in treatment with injectable diacetylmorphine. Given worsening trends in the addiction and overdose crisis in the US, treatment with injectable diacetylmorphine should be considered as another evidence-based option for treating OUD. KEY MESSAGES: Interest in treatment with injectable diacetylmorphine was high among a sample of people who use opioids in the United States. Factors associated with increased interest in treatment with injectable diacetylmorphine included having at least a high school education, having ever overdosed, and not having health insurance. Past utilization of medications for opioid use disorder was associated with interest in treatment with injectable diacetylmorphine. Taylor & Francis 2023-04-20 /pmc/articles/PMC10120460/ /pubmed/37078710 http://dx.doi.org/10.1080/07853890.2023.2196435 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Addiction
Allen, Sean T.
Schneider, Kristin E.
Rouhani, Saba
White, Rebecca Hamilton
Morris, Miles
Owczarzak, Jill
Sherman, Susan G.
Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
title Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
title_full Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
title_fullStr Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
title_full_unstemmed Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
title_short Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)
title_sort interest in treatment with injectable diacetylmorphine among people who use opioids in baltimore city, maryland (usa)
topic Addiction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120460/
https://www.ncbi.nlm.nih.gov/pubmed/37078710
http://dx.doi.org/10.1080/07853890.2023.2196435
work_keys_str_mv AT allenseant interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa
AT schneiderkristine interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa
AT rouhanisaba interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa
AT whiterebeccahamilton interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa
AT morrismiles interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa
AT owczarzakjill interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa
AT shermansusang interestintreatmentwithinjectablediacetylmorphineamongpeoplewhouseopioidsinbaltimorecitymarylandusa